Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc. (DVA) Form 4: Chief Compliance Officer James O. Hearty sold 2,351 common shares on 07/23/2025 at $150.00 each under a pre-arranged Rule 10b5-1 trading plan adopted 03/17/2025. The transaction reduced his direct holdings from an estimated 28,389 to 26,038 shares, a decline of roughly 8.3%. No derivative securities were involved. The filing was signed by an attorney-in-fact on 07/24/2025.
The sale represents a modest portion of the insider’s stake and was executed via an automated plan, which may limit informational value regarding management’s outlook. Investors typically monitor insider activity for sentiment signals, trading-plan usage, and potential supply impacts on the stock’s float.